PURPOSE: Quantitative imaging of the type 1 cannabinoid receptor (CB1R) opens perspectives for many neurological and psychiatric disorders. We characterized the kinetics and reproducibility of the CB1R tracer [(18)F]MK-9470 in human brain. METHODS: [(18)F]MK-9470 data were analysed using reversible models and the distribution volume V (T) and V (ND) k (3) (V (ND) k (3) = K (1) k (2)) were estimated. Tracer binding was also evaluated using irreversible kinetics and the irreversible uptake constant K (i) and fractional uptake rate (FUR) were estimated. The effect of blood flow on these parameters was evaluated. Additionally, the possibility of determining the tracer plasma kinetics using a reduced number of blood samples was also examined. RESULTS: A reversible two-tissue compartment model using a global k (4) value was necessary to describe brain kinetics. Both V (T) and V (ND) k (3) were estimated satisfactorily and their test-retest variability was between 10% and 30%. Irreversible methods adequately described brain kinetics and FUR values were equivalent to K (i). The linear relationship between K (i) and V (ND) k (3) demonstrated that K (i) or FUR and thus the simple measure of tracer brain uptake provide CB1R availability information. The test-retest variability of K (i) and FUR was <10% and estimates were independent of blood flow. Brain uptake can be used as a receptor availability index, albeit at the expense of potential bias due to between-subject differences in tracer plasma kinetics. CONCLUSION: [(18)F]MK-9470 specific binding can be accurately determined using FUR values requiring a short scan 90 to 120 min after tracer administration. Our results suggest that [(18)F]MK-9470 plasma kinetics can be assessed using a few venous samples.
PURPOSE: Quantitative imaging of the type 1 cannabinoid receptor (CB1R) opens perspectives for many neurological and psychiatric disorders. We characterized the kinetics and reproducibility of the CB1R tracer [(18)F]MK-9470 in human brain. METHODS: [(18)F]MK-9470 data were analysed using reversible models and the distribution volume V (T) and V (ND) k (3) (V (ND) k (3) = K (1) k (2)) were estimated. Tracer binding was also evaluated using irreversible kinetics and the irreversible uptake constant K (i) and fractional uptake rate (FUR) were estimated. The effect of blood flow on these parameters was evaluated. Additionally, the possibility of determining the tracer plasma kinetics using a reduced number of blood samples was also examined. RESULTS: A reversible two-tissue compartment model using a global k (4) value was necessary to describe brain kinetics. Both V (T) and V (ND) k (3) were estimated satisfactorily and their test-retest variability was between 10% and 30%. Irreversible methods adequately described brain kinetics and FUR values were equivalent to K (i). The linear relationship between K (i) and V (ND) k (3) demonstrated that K (i) or FUR and thus the simple measure of tracer brain uptake provide CB1R availability information. The test-retest variability of K (i) and FUR was <10% and estimates were independent of blood flow. Brain uptake can be used as a receptor availability index, albeit at the expense of potential bias due to between-subject differences in tracer plasma kinetics. CONCLUSION: [(18)F]MK-9470 specific binding can be accurately determined using FUR values requiring a short scan 90 to 120 min after tracer administration. Our results suggest that [(18)F]MK-9470 plasma kinetics can be assessed using a few venous samples.
Authors: Jon-Kar Zubieta; Mary M Heitzeg; Yanjun Xu; Robert A Koeppe; Lisong Ni; Sally Guthrie; Edward F Domino Journal: Am J Psychiatry Date: 2005-03 Impact factor: 18.112
Authors: Koen Van Laere; Michel Koole; Sandra M Sanabria Bohorquez; Karolien Goffin; Ilonka Guenther; Marie J Belanger; Josee Cote; Paul Rothenberg; Inge De Lepeleire; Igor D Grachev; Richard J Hargreaves; Guy Bormans; H Donald Burns Journal: J Nucl Med Date: 2008-02-20 Impact factor: 10.057
Authors: Garth E Terry; Jeih-San Liow; Sami S Zoghbi; Jussi Hirvonen; Amanda G Farris; Alicja Lerner; Johannes T Tauscher; John M Schaus; Lee Phebus; Christian C Felder; Cheryl L Morse; Jinsoo S Hong; Victor W Pike; Christer Halldin; Robert B Innis Journal: Neuroimage Date: 2009-06-30 Impact factor: 6.556
Authors: M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice Journal: Proc Natl Acad Sci U S A Date: 1990-03 Impact factor: 11.205
Authors: Marc D Normandin; Ming-Qiang Zheng; Kuo-Shyan Lin; N Scott Mason; Shu-Fei Lin; Jim Ropchan; David Labaree; Shannan Henry; Wendol A Williams; Richard E Carson; Alexander Neumeister; Yiyun Huang Journal: J Cereb Blood Flow Metab Date: 2015-04-01 Impact factor: 6.200
Authors: Jussi Hirvonen; Garth E Terry; Christer Halldin; Victor W Pike; Robert B Innis Journal: Eur J Nucl Med Mol Imaging Date: 2010-05 Impact factor: 9.236
Authors: Caroline Vandeputte; Cindy Casteels; Tom Struys; Michel Koole; Daisy van Veghel; Nele Evens; Anneleen Gerits; Tom Dresselaers; Ivo Lambrichts; Uwe Himmelreich; Guy Bormans; Koen Van Laere Journal: Eur J Nucl Med Mol Imaging Date: 2012-08-16 Impact factor: 9.236